GlassScriptPhysician profile
Mackenzie E Mauss
NPI 1548820202
$1,591.57
in general payments reported to CMS, 2019-2025
24 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $226 · 2023: $297 · 2024: $434 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $243.64 | 2022-2023 | Bexsero |
| Pfizer INC. | $203.66 | 2022-2024 | |
| Exact Sciences Corporation | $149.21 | 2023-2025 | Cologuard Collection Kit |
| Biomarin Pharmaceutical INC. | $116.41 | 2025 | Voxzogo 1.2mg |
| Bayer Healthcare Pharmaceuticals INC. | $102.19 | 2024 | |
| Vanda Pharmaceuticals INC. | $85.58 | 2022-2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $73.68 | 2021-2024 | Gardasil, Vaqta, M-M-R II |
| Sumitomo Pharma America, INC. | $67.99 | 2023-2024 | Aptiom |
| Cranial Technologies, INC | $56.58 | 2021-2022 | |
| Novo Nordisk INC | $54.11 | 2021-2025 | Rybelsus |
| Sanofi Pasteur INC. | $53.57 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $48.76 | 2021-2025 | |
| Amgen INC. | $47.41 | 2025 | Otezla, Repatha |
| Evoke Pharma, INC. | $46.24 | 2021 | |
| Medtronic, INC. | $42.10 | 2024 | Minimed 780g |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.21 | 2021 | |
| Madrigal Pharmaceuticals | $29.79 | 2025 | Rezdiffra |
| Lilly USA, LLC | $27.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.50 | 2024 | Flumist Quadrivalent |
| Hologic Sales and Service, LLC | $22.13 | 2021 | |
| Genentech USA, INC. | $21.90 | 2021 | |
| Averitas Pharma INC. | $16.57 | 2023 | Qutenza |
| Phadia US INC. | $13.66 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Mauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.